Pharmacogenomics
Social, Ethical, and Clinical Dimensions
Published on 9. April 2003
368 pages
978-0-471-46120-3 (ISBN)
Description
Through analyses of the complex underlying issues, thisinterdisciplinary volume frames the agenda for dealing with geneticvariation and incorporating pharmacogenomics into health care. Thethree sections of this book, Research Issues, Clinical Issues, andSocial Perspectives address key elements integral to acomprehensive discussion of this emerging field.
This groundbreaking text...
* Examines new research strategies, methodologies, and ethicaland social considerations of pharmacogenomics
* Addresses practical considerations of anticipated changes ineducation, training, oversight, guidelines and protocols, andcontinuing education requirements
* Provides analyses of the potential enormous impact ofpharmacogenomics, such as in the standard of care and treatment,including perspectives from the fields of anthropology, law,ethics, and economics
Reviews / Votes
"The discussion of societal, legal, economic, and governmentalissues go well beyond the sphere of pharmogenomics." (AmericanJournal for Medical Genetics, September 1, 2005) "...indispensable guide...as timely as it can be...an impressivemultidisciplinary analysis...a 'must read'..." (Bioethics,Vol 18(4), August 2004) "...Pharmacogenomics is highly recommended for anyonewith an interest in the field.... Given this book'suniqueness...libraries at any institution teachingpharmcogenomics should have a copy of this book." (Journalof Pharmacy Technology, Sept/Oct 2003) "...well written, clear, and informative...a restrained sense ofexcitement...permeates throughout...clearly...a solid contributionto the discourse." (Nature Biotechnology, May 1, 2003) "...chapters offer fascinating glimpses into fields that may notbe familiar to geneticists, genomicists, or clinicians...they willbe informative...and provide a reminder that many people outsidethis field are going to be paying a lot of attention asdiscoveries...are reported." (New England Journal ofMedicine, July 24, 2003) "...an excellent summary of aspects of phamacogenomics...a solidreference for those working in the field and a unique textbook forthose new to the subject area." (Clinical Chemistry, Vol.49, No. 9) "...a welcome addition to the growing body ofliterature...highly recommended for anyone with an interest in thefield...should be required reading for anyone conductingpharmacogenomic research and for all clinicians who usepharmacogenomics..." (Journal of Pharmacy Technology, Vol.19September/October 2003) "...addresses the ethical, legal, and social implications of theindividualized medicine that pharmacogenomics stands to create..."(Genetic Engineering News, Vol 23(14), 2003)"This volume presents the ethical, legal and social issues as theyinterface with pharmacogenomics in a very readable and accessiblemanner...this is an incredibly valuable guide by thought-leaders inthe field." --Edward R. B. McCabe, M.D., Ph.D., David Geffen School of Medicineat UCLA, Los Angeles, CaliforniaMore details
Other editions
Additional editions
Software
03/2003
Wiley
€51.72
No shipping information available
Book
01/2003
1st Edition
Wiley
€132.50
Shipment within 10-20 days
Person
Mark A. Rothstein holds the Herbert F. Boehl Chair of Law and Medicine and is Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville. He has appointments in the Departments of Medicine and Family and Community Medicine at the School of Medicine and at the Louis D. Brandeis School of Law. Professor Rothstein is a leading authority on genetics, privacy, and health policy. He has served as an advisor to the NIH, CDC, DOE, Institute of Medicine, National Conference of State Legislatures, and numerous other public and professional entitles.
Content
Foreword (F. Collins).
Preface.
PART I: INTRODUCTION: SCIENCE AND SOCIETY.
Public Attitudes About Pharmacogenomics (M. Rothstein, etal.).
Pharmacogenomics: Pharmacology and Toxicology in theGenomics (H. Mohrenweiser).
The Implications of Population Genetics for Pharmacogenomics (C.Hanis).
PART II: RESEARCH AND DEVELOPMENT CHALLENGES ANDCONSIDERATIONS.
Genome Research and Minorities (H. Greely).
Drug Development Strategies (P. Manasco & T. Arledge).
Drug Development, Regulation, and Genetically GuidedTherapy Pharmacogenomics (D. Feigal & S. Gutman).
Intellectual Property and Commercial Aspects of Pharmacogenomics(A. Nunnally, et al.).
PART III: CLINICAL APPLICATIONS.
Integration of Pharmacogenomics into Medical Practice (G. Omenn& A. Motulsky).
Clinical Utility Pharmacogenetics and Pharmacogenomics (N.Holtzman).
Medical Liability for Pharmacogenomics (L. Palmer).
The Challenges of Pharmacogenomics for Pharmacy Education,Practice, and Regulation (D. Brushwood).
PART IV: THE SOCIAL DIMENSION.
Economic Implications of Pharmacogenomics (C. Reeder & W.Dickson).
Pharmacogenomics and the Social Construction of Identity(M. Foster).
Pharmacogenomics: Considerations for Communities of Color (L.Nsiah-Jefferson).
Constitutional Issues in the Use of Pharmacogenomic VariationsAssociated with Race (J. Robertson).
PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).
Pharmacogenomics and Minority Populations: General PopulationSurvey Questionnaire (M. Rothstein).
Index.
